[Press Release] PCMO Partners with MirimGENE Co., Ltd. to Develop Tuberculosis Treatment미생물실증지원센터 공식 홈페이지

HOME

[Press Release] PCMO Partners with MirimGENE Co., Ltd. to Develop Tuberculosis Treatment

ER
2024.07.16

- Targeting the tuberculosis treatment market, projected to reach approximately $3 billion (₩4.13 trillion) by 2030… Aiming at a high-risk disease with a 12% mortality rate

20240716 미생물실증지원센터-(주)미림진 로고.jpg

▲ PCMO-MirimGENE Co. logo

PCMO (Director Min Cho, hereafter referred to as the Center) announced on the 16th that it is collaborating with MirimGENE Co., Ltd. (CEO Mirim Jin) to jointly develop a ‘recombinant protein treatment for tuberculosis’ based on an innovative drug platform targeting WARS1 (Tryptophanyl tRNA synthetase 1).

WARS1 is an endogenous human factor that is secreted into the blood from monocytes within minutes of infection, activating innate immunity.

MirimGENE Co., Ltd. has been the first in the world to elucidate the immune activation function and mechanism of action of WARS1 and is developing a first-in-class innovative drug targeting it. MirimGENE Co., Ltd. possesses a robust pipeline of treatments not only for tuberculosis but also for over-inflammatory sepsis, rheumatoid arthritis, atopic dermatitis, and other autoimmune and rare diseases, as well as infectious diseases, using its proprietary new drug development technology with the WITheranostics platform (WARS1 targeted-Immune disorder Theranostics).

The Center, with its extensive experience in various contract development and manufacturing (CDMO) projects since obtaining GMP certification in 2021, will cooperate to accelerate the research and development of MirimGENE Co., Ltd.’s tuberculosis treatment and bring it to market. The Center has significant experience in tuberculosis vaccine research and development, instilling confidence in the success of this project.

Meanwhile, the market for tuberculosis treatment, targeted by MirimGENE Co., Ltd., is expected to grow to approximately $3 billion (₩4.13 trillion) by 2030. According to the World Health Organization’s 2022 Global Tuberculosis Report, approximately 10.6 million people were infected, with the death toll reaching 1.3 million, highlighting the high mortality rate and the critical need for new drug development.